

D' international application PCT/EP93/00770 filed March 30, 1993, which in turn claims foreign priority to European application 92400902, filed 03/31/92.--

IN THE CLAIMS:

✓ ✓
Please cancel Claims 27 and 28 without prejudice or disclaimer of the subject matter contained therein.

Please amend the following Claims:

D²
--23. (Amended) [A] An isolated peptide or polypeptide which is a fragment of the extracellular portion of the interferon receptor (IFN-R) of SEQ ID NO: 1 or 2, said peptide or polypeptide consisting of an amino acid [residue] sequence from position 27 to [amino acid residue] position 427 of SEQ ID NO: 1 or 2 or a portion thereof; wherein said peptide or polypeptide specifically binds to monoclonal-antibody 64G12 [(]deposited at the ECACC under no. 92022605[)].

Sub E'
24. (Amended) [A] An isolated peptide or polypeptide [as claimed in claim 23], consisting of an amino acid sequence from position [residue] 27 to [amino acid residue] position 229 of SEQ ID NO: 1 or 2 or a portion thereof.

25. (Amended) [A] An isolated peptide or polypeptide which is a fragment of the extracellular portion of the interferon receptor (IFN-R) of SEQ ID NO: 1 or 2, said peptide or polypeptide consisting of an amino acid [residue] sequence from position 1 to [amino acid residue] position 229 of SEQ ID NO: 1 or 2 or a portion thereof; wherein said peptide or polypeptide specifically binds to monoclonal antibody 64G12.--

REMARKS

Entry of the foregoing and favorable reconsideration and reexamination of the subject application, as amended, pursuant to and consistent with 37 C.F.R. § 1.112, and in light of the remarks which follow, are respectfully requested.

By the present amendment, the specification has been amended to provide accurate information regarding claim to priority of this application. Claims 27 and 28 have been cancelled since they are drawn to a non-elected invention.